Subscribe: Market Wire - Pharmaceuticals and Biotech: Trials
http://img.marketwire.com/rss/mwPBTR.rss
Preview: Market Wire - Pharmaceuticals and Biotech: Trials

Marketwired - Trials



Marketwired - Trials



Last Build Date: Thu, 21 Sep 2017 08:33:13 EDT

Copyright: Copyright: (C) Marketwired
 



American Cannabis Company, Inc. Signs Exclusive Distribution Agreement with Earth Alive

Thu, 21 Sep 2017 08:30:00 EDT

DENVER, CO--(Marketwired - Sep 21, 2017) - American Cannabis Company, Inc. (OTCQB: AMMJ) ("ACC"), a full-service business-to-business consulting solutions provider, and seller of ancillary products to the cannabis industry, today announced it has signed an exclusive distribution agreement with Earth Alive, a leading Canadian clean-tech company that develops and manufactures state-of-the-art microbial technology-based products. This agreement allows for the commercialization of Earth Alive's premiere cannabis microbial inoculant product, called Dr. Marijane. Dr. Marijane is a certified organic root probiotic that promotes increased vegetative growth, improves the bioavailability of fertilizer programs, and sustains healthy development and structuring of plant roots.




Pharma Competitive Intelligence: Delivering Actionable Insights for Decision Making, New Webinar Hosted by Xtalks

Thu, 21 Sep 2017 07:30:00 EDT

TORONTO, ON--(Marketwired - September 21, 2017) - In a live webinar taking place on Tuesday, October 10, 2017 at 10am EDT (3pm BST/UK) industry experts Jamie Munro, Global Practice Leader of Portfolio and Licensing and Karthik Subramanian, Senior Product Strategy Manager, both from Clarivate Analytics, will provide insight into current Pharma CI, including trends and best practices.




Electronic Informed Consent: 2017 Industry Survey Results from Clinical Sites, New Webinar Hosted by Xtalks

Thu, 21 Sep 2017 07:00:00 EDT

TORONTO, ON--(Marketwired - September 21, 2017) - It's an exciting time for the life sciences industry, with technology driving greater levels of efficiency, effectiveness and patient engagement and satisfaction in clinical trials.




Breathtec Biomedical Announces Resignation of Chief Executive Officer

Wed, 20 Sep 2017 17:05:06 EDT

VANCOUVER, BC--(Marketwired - Sep 20, 2017) -  Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the "Company") announces that effective immediately, Guy La Torre has resigned as Director and Chief Executive Officer ("CEO") of the Company to pursue other ventures. The Company wishes Guy the best with his future endeavours. An interim CEO will be appointed in due course. 




First Harvest Issues Shareholder Update

Wed, 20 Sep 2017 11:47:26 EDT

Highlights Recent Developments, Milestones and New Business Opportunities




Sir Andrew Witty, Former CEO of GSK, Joins Synthego Advisory Board

Wed, 20 Sep 2017 09:03:00 EDT

Synthego strengthens position with appointment while accelerating worldwide commercial growth




SANUWAVE Announces Exhibition at Medica in Cooperation With State of Georgia; Visit us at Booth 16D10-8 in Hall 16

Wed, 20 Sep 2017 09:00:00 EDT

SUWANEE, GA--(Marketwired - Sep 20, 2017) - SANUWAVE Health, Inc. (OTCQB: SNWV) is pleased to announce that the company will exhibit, in conjunction with Georgia Department of Economic Development, at MEDICA in Dusseldorf, Germany on 13 -16 November 2017. SANUWAVE cordially invites you to our section of booth 16D10-8 in Hall 16. MEDICA is the world's leading trade fair for the medical industry. SANUWAVE is using this occasion to further educate on our lead wound care product, dermaPACE® and our industry leader for the treatment of various orthopedic conditions, orthoPACE®.




CFN Media Exclusive Interview with United Cannabis: Developing Anti-Inflammatory Pharmaceuticals

Wed, 20 Sep 2017 09:00:00 EDT

SEATTLE, WA--(Marketwired - Sep 20, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an exclusive interview with United Cannabis Corp.'s (OTCQB: CNAB) Chief Science Officer Dr. Brent Reynolds, PhD. In the interview, Dr. Reynolds discusses the importance of clinical development and how the company's recent acquisition of Prana Therapeutics plays into its overall strategy.




True Leaf: Crowdfunding Legal Cannabis Products Across North America -- CFN Media

Wed, 20 Sep 2017 09:00:00 EDT

SEATTLE, WA--(Marketwired - Sep 20, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article examining True Leaf Medicine International Ltd. (CSE: MJ) (CNSX: MJ) (MJ.CN) (OTCQB: TRLFF) and its pending Regulation A+ public offering that is giving anyone the opportunity to invest in hemp and cannabis products that will be fully legal in both the U.S. and Canada. True Leaf's mission is to create safe, natural cannabis based products that enhance the quality of life for both people and pets. The company already has pet products in the market, and is in the final stages of Canadian approval to grow and sell legal cannabis.




ABcann Global Enters Its Growth Phase (Plus Exclusive Interview) -- CFN Media

Wed, 20 Sep 2017 09:00:00 EDT

SEATTLE, WA--(Marketwired - Sep 20, 2017) -  CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an exclusive interview with ABcann Global Corporation's (TSX VENTURE: ABCN) (OTCQB: ABCCF) Aaron Keay, former CEO and current member of the Board of Directors. In the interview, Mr. Keay discusses the company's transition to new CEO Barry Fishman, as well as the opportunities ahead for the company in both Canada and internationally.




Abattis Prepares for Growth in Extracts -- CFN Media

Wed, 20 Sep 2017 08:30:00 EDT

SEATTLE, WA--(Marketwired - Sep 20, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article discussing Abattis Bioceuticals Corp. (CSE: ATT) (ATT.CN) (CNSX: ATT) (OTCQB: ATTBF) and why its proprietary extraction technology represents an important breakthrough that shouldn't be ignored. While many licensed producers are focused on expanding capacity, the best opportunities may be those that can add value for existing licensed producers. These opportunities include those companies focused on higher value cannabis extracts.




NetworkNewsWire Announces Publication Highlighting Recent Developments in Drug Delivery Technologies

Wed, 20 Sep 2017 08:30:00 EDT

NEW YORK, NY--(Marketwired - Sep 20, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a client of NNW that develops and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids.




InMed Pharma: A Leader in Cannabinoid Biosynthesis -- CFN Media

Wed, 20 Sep 2017 08:30:00 EDT

SEATTLE, WA--(Marketwired - Sep 20, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article covering how InMed Pharmaceuticals Inc. (CSE: IN) (CNSX: IN) (IN.CN) (OTCQB: IMLFF) is leveraging biosynthesis to solve a major problem in the medical cannabis industry as it adds key ex-Eli Lilly personnel to its efforts.




Treos Bio Enters into Agreement with PPD to Manage First-in-Man Trial of Its Lead Therapeutic Cancer Vaccine Program

Wed, 20 Sep 2017 08:15:00 EDT

SAN FRANCISCO, CA and LONDON, UNITED KINGDOM--(Marketwired - Sep 20, 2017) - Treos Bio Limited, which is developing precision peptide cancer vaccines coupled with companion diagnostics, today announced it has entered into an agreement with Pharmaceutical Product Development, LLC (PPD), a leading global contract research organization. As part of the agreement, PPD® Biotech, a PPD service dedicated to biotech and small to mid-sized pharmaceutical companies, will manage Treos Bio's first-in-man study of its lead therapeutic cancer vaccine for metastatic colorectal cancer. This study will be conducted in the United States and Europe.




Strategy Design & Formulation Considerations for GLP Toxicology Studies, New Webinar Hosted by Xtalks

Wed, 20 Sep 2017 07:30:00 EDT

TORONTO, ON--(Marketwired - September 20, 2017) - A lack of planning for a new compound's GLP toxicology study can severely trip up your IND. Upfront planning to design a successful toxicology study, identify problems and allow time for solutions can help avoid costly delays. Toxicology study design requires a customized strategy that is relevant to the intended clinical indication and route of administration and is acceptable to regulatory authorities. Formulation development plays an important role in assessing the in-vivo properties of a molecule during preclinical development, such as overcoming solubility issues and maximizing exposure.




Next Generation Data Mapping and Analytics Solutions Improve the Speed and Quality of Preparing Data Submissions for FDA, New Webinar Hosted by Xtalks

Wed, 20 Sep 2017 07:00:00 EDT

TORONTO, ON--(Marketwired - September 20, 2017) - FDA now requires drug development firms pursuing approvals to submit all clinical data in CDISC standards such as the Study Data Tabulation Model (SDTM). To meet this requirement, many companies are using labor-intensive, manual and error-prone data extraction and mapping techniques.




Dr. Patrick M. Fratellone Joins Canbiola, Inc. (CANB) as Medical Advisor and Distributor

Tue, 19 Sep 2017 10:30:00 EDT

HICKSVILLE, NY--(Marketwired - Sep 19, 2017) - Canbiola, Inc. (OTC PINK: CANB) announced today that the company has added Dr. Fratellone to its Medical Advisory Board and engaged Dr. Fratellone as a distributor for Canbiola products. Dr. Fratellone is an attending physician at St. Luke's Hospital, Roosevelt Hospital, and Beth Israel Hospital, and current professor at University of Bridgeport College of Naturopathic Medicine. In addition, he bridges East Meets West at the Center of Excellence in Bridgeport CT with author Dr. Peter D'Adamo of Eat Right for Your Blood Type. Dr. Fratellone has appeared on multiple shows, and is considered an expert in his field as well a visionary. Dr. Fratellone stated, "As one of the few MDs in the US who is also a registered herbalist, I believe in traditional and time honored treatments, but also to look outside of the box; to that end CBD is certainly part of the future in my opinion with clear benefits to patients. I look forwarded to working with Canbiola, as well as educating the public on the vast benefits of CBD through blogs and speaking engagements."




FDA Grants ALRT Clearance for Insulin Dose Adjustment (IDA) Feature

Tue, 19 Sep 2017 10:02:29 EDT

IDA is designed to ensure that patients get an effective and timely insulin dose(s) based on accurate data about their specific needs




Avadim Technologies Inc. Announces Partnership With Cardinal Health, Inc.

Tue, 19 Sep 2017 09:15:00 EDT

Cardinal Health, a Global, Integrated Healthcare Services and Products Company Ranked #15 of Fortune 500 Companies, Will Now Supply Theraworx(R) Technology to its Acute Care and Long-Term Care Customers




Pivot Pharma Looks to Improve Cannabinoid Bioavailability with Topical BiPhasix(TM) Delivery System -- CFN Media

Tue, 19 Sep 2017 09:00:00 EDT

SEATTLE, WA--(Marketwired - Sep 19, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article examining Pivot Pharmaceuticals Inc. (OTCQB: PVOTF) and its recent acquisition of the BiPhasixT Transdermal Drug Delivery technology for the delivery of cannabinoids.




Medovex Corporation Launches DenerveX System in Spain with Distributor Prim SA

Tue, 19 Sep 2017 08:30:00 EDT

Training and First Order Scheduled for Week of September 19th




Cannabis Science "Nanoparticle Drones to Target Lung Cancer with Radiosensitizers and Cannabinoids" Full Publication Released Today In Frontiers In Oncology

Tue, 19 Sep 2017 08:18:05 EDT

IRVINE, CA--(Marketwired - Sep 19, 2017) -  Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, announces the full publication of initial research results on using nanoparticle drones to target lung cancer with radiosensitizers and cannabinoids in the world-renowned cancer research journal, Frontiers in Oncology, released today.




Graybug Vision Initiates Phase 1/2 Trial of GB-102 for Wet Age-related Macular Degeneration

Tue, 19 Sep 2017 08:00:00 EDT

Novel Injectable Formulation for Potential Twice Per Year Treatment




Pharmacology to Payer: One Quantitative Drug Development Framework to Rule Them All

Tue, 19 Sep 2017 07:30:00 EDT

TORONTO, ON--(Marketwired - September 19, 2017) - This webinar will discuss how "pharmacology to payer" (P2P) can be used as a quantitative framework that bridges the disciplines of pharmacology, epidemiology, and health economics to support meaningful dialogue between industry, regulators, and payers.




Biologics in Dermatology: Considerations for Patients and Clinical Trials, New Webinar Hosted by Xtalks

Tue, 19 Sep 2017 07:00:00 EDT

TORONTO, ON--(Marketwired - September 19, 2017) - In an upcoming presentation experts Darcee Duke Strube, Senior Vice President of Novella Clinical's Dermatology Division and Dr. James J Milbauer, Dermatologist, Medical Monitor and Advisor will discuss the evolution of biologics within the dermatology landscape, with an emphasis on clinical trial considerations for sponsors developing biologic agents.




Industry Leader, Darren Cherry, Leads Advantis Corp. Into the Future

Tue, 19 Sep 2017 01:53:03 EDT

NEWPORT BEACH, CA--(Marketwired - Sep 19, 2017) - ADVANTIS CORPORATION (OTC PINK: ADVT) announced that it has agreed with leading wholesale, marketing, and logistics expert, Darren Cherry, to take the helm as its new CEO.




FRDJ et la Financière Sun Life font équipe pour amasser des fonds destinés à la recherche sur le diabète

Mon, 18 Sep 2017 16:33:42 EDT

La Révolution FRDJ Roulons met les Canadiens au défi de se dépasser et de récolter de l'argent pour vaincre le diabète de type 1




JDRF and Sun Life Financial team up to raise funds for diabetes research

Mon, 18 Sep 2017 16:33:07 EDT

The JDRF Revolution Ride challenges Canadians to go further and raise funds to defeat type 1 diabetes




Medigus Announces Second Quarter 2017 Financial Results

Mon, 18 Sep 2017 16:05:00 EDT

OMER, ISRAEL--(Marketwired - Sep 18, 2017) - Medigus Ltd. (NASDAQ: MDGS) (TASE: MDGS), a medical device company developing minimally invasive endosurgical tools and direct visualization technology, today announced financial results for the second quarter ended June 30, 2017.




Pressure BioSciences' Next-Generation Barocycler 2320EXTREME Named a Finalist in the Prestigious 2017 R&D 100 Awards

Mon, 18 Sep 2017 09:46:37 EDT

Considered Among the Most Prestigious Recognitions of Invention and Innovation Worldwide, the R&D 100 Awards Identify the Top 100 Revolutionary Technologies of the Past Year




GeoVax Provides Update on its Zika Vaccine Development

Mon, 18 Sep 2017 09:00:00 EDT

Presentation Made During 11th Vaccine Congress in San Diego




MediXall Group, Inc. Creates Multiple Revenue Streams in September 2017

Mon, 18 Sep 2017 08:00:00 EDT

FT. LAUDERDALE, FL--(Marketwired - Sep 18, 2017) - MediXall Group, Inc. (OTCQB: MDXL) announced today that three additional revenue streams are in place and operational, creating additional value in the company. The mission of the MediXall Group is to revolutionize the medical industry by improving communication; providing better technology and support services; and enabling more efficient, cost-effective healthcare for the consumer. Prior to the planned October launch of the MediXaid Healthcare Platform, a subsidiary of MediXall Group with over 3,500 practitioners and diagnostic centers participating, to date, the company has signed agreements with strategic partners, SafeRide and PWeR®, who offer strong solutions to help network practitioners grow their businesses.




What Does it Take to Successfully Execute Large, Global, Phase III Programs?

Mon, 18 Sep 2017 07:30:00 EDT

TORONTO, ON--(Marketwired - September 18, 2017) - In a complimentary webinar taking place on Tuesday, October 3, 2017 at 10am EDT (3pm BST/UK), INC Research/inVentiv Health leaders Clifford McIntosh, Vice President of Strategic Alliance Management and Alexandria Wise-Rankovic, Ph.D., Senior Vice President of Clinical Development, CNS reveal a proven method to thrive in large, global, Phase III Programs.




Why Track and Trace Isn't Just Tracking and Tracing: Best Practices for Implementing a Solution That Works

Mon, 18 Sep 2017 07:00:00 EDT

TORONTO, ON--(Marketwired - September 18, 2017) - In an upcoming webinar on Wednesday, October 4, 2017, industry expert Joe Lipari, Director of Cloud Products at Systech International will discuss a holistic approach towards designing and achieving a successful Track and Trace solution.




REMINDER - Optymyze to Highlight Best Practices for Leveraging Sales Data at PharmaForce 2017

Mon, 18 Sep 2017 07:00:00 EDT

CHESTER, PA--(Marketwired - Sep 18, 2017) -




Lugano 2014 Criteria for Assessing FDG-PET/CT in Lymphoma: An Operational Approach for Clinical Trials

Fri, 15 Sep 2017 08:15:21 EDT

The goal of this webinar hosted by Xtalks is to discuss the evolution of the role of imaging in the assessment of lymphomatous disease




Development and Manufacture of HPAPI Drug Products through the Clinical Phases from molecule to market, New Webinar Hosted by Xtalks

Fri, 15 Sep 2017 08:12:31 EDT

TORONTO, ON--(Marketwired - September 15, 2017) - This webinar will share how highly potent APIs can be developed and manufactured into suitable drug dosage forms including; solid oral, non-sterile oral liquids and semi-solid creams and ointments whilst adhering to the highest quality standards. Attendees will learn about the complexities at each stage of the development lifecycle, from the earliest phase of First in Man (FiM) studies involving drug in capsule, moving through ongoing clinical development and process optimization of often complex formulations ultimately resulting in commercialization and global supply.




Most Surveyed Pharma Companies Choose to Fund Dedicated Continuing Medical Education Programs

Thu, 14 Sep 2017 18:51:00 EDT

RESEARCH TRIANGLE PARK, NC--(Marketwired - September 14, 2017) - About 77% of surveyed global medical affairs teams consider dedicated CME providers as their first choice when funding continuing medical education (CME) programs, according to a recent study by industry intelligence provider, Cutting Edge Information.




Tauriga Sciences, Inc. Secures $210,000 in Long Term Financing from Existing Institutional Investor

Thu, 14 Sep 2017 10:26:28 EDT

NEW YORK, NY--(Marketwired - Sep 14, 2017) - Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company"), a company engaged in building businesses in the life sciences space, today announced that it has secured $210,000 in long term financing from an existing institutional investor. Under terms of the financing agreement, the Company received $30,000 USD upon signing with the balance of $180,000 being deferred until after March 11, 2018. The financing structure consists of one $30,000 convertible debenture with 6 distinct $30,000 "Back End" convertible debentures which are eligible to be funded at any time between March 11, 2018 -- September 11, 2018. A detailed disclosure of the material terms of this financing agreement will be provided to shareholders on Form 8-K to be filed by the Company within the next few business days.




CureDots(TM) Look to Redefine How Animal Clinical Trials Are Conducted -- CFN Media

Thu, 14 Sep 2017 09:30:00 EDT

SEATTLE, WA--(Marketwired - Sep 14, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article examining CURE Pharmaceutical's (OTCQB: CURR) recently developed CureDotsT, a more humane and effective technique for administering drugs to animals.